Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings
Argenx came into this Q3 2026 report with a rich biotech valuation and a reputation as a high conviction growth story. Yet the stock closed at €782.2 on 23 October, roughly flat over the past week and soft over the past month, which signals a market still debating how much is already priced in.
The headline this quarter is simple. Product sales reached about US$1.7b and basic earnings per share were US$8.07. That level of earnings power, paired with a trailing net margin of 31.7%, indicates a stronger profitability profile than the muted one day share price reaction might suggest.
Like argenx’s earnings strength but unsure how much optimism is already reflected in the share price? Compare it with other profitable growth plays using our 192 high quality undervalued stocks
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025): US$1,751 million vs. US$1,151.338 million (very large increase in quarterly top line)
-
Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): US$506 million vs. US$344.258 million (very large rise in quarterly profit)
-
Basic EPS (Q3 2026 vs Q3 2025): US$8.07 vs. US$5.61 (very large uplift in earnings per share)
-
Trailing Net Profit Margin (TTM Q3 2026 vs prior year): 31.7% vs. 41.6% (profitability remains solid but margin has compressed)
VYVGART is surging while argenx spends heavily to build new pillars. Ask Charlie what makes argenx’s Vision 2030 plan believable.
Argenx Tests Its Multi Platform Ambition
The bullish story around argenx hinges on whether VYVGART can be just the starting point for a broader immunology portfolio. The narrative sets a clear ambition.
“The addition of FB102 from the Forte acquisition now reframes argenx as a two platform immunology company with a broader potential earnings base.”
Q3 results show early steps toward that claim. VYVGART still carries the financial load, reflected in the US$1.7b product sales and 31.7% trailing margin. FB102 now arrives with positive Phase 2 celiac data and a planned Phase 3, and sits alongside empasiprubart heading into a registrational MMN readout in December 2026.
One Narrative disagrees with today’s price. →See where this Narrative says argenx should trade.
Argenx Spending Plan: Costs Rising Faster Than Fear
Bearish investors worry that argenx is stretching itself, loading up on programs and overhead that earnings cannot support.
“the higher combined R&D and SG&A expectations of about US$4b in 2026, up roughly 45% versus 2025, create a risk that the broader cost base grows faster than incremental product uptake, which could cap operating margin expansion and dampen earnings growth.”
